Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier

Biotechnology and Bioengineering

Volumn 96, Issue 2, 2007, Pages 381-391

  Boado, Ruben J ^a,b   Zhang, Yufeng ^a   Zhang, Yun ^a,b   Pardridge, William M ^b  

^a ArmaGen Technologies Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Drug targeting; Endothelium; Rhesus monkey

Indexed keywords

AMINO ACIDS; BLOOD; BRAIN; BRAIN MODELS; DRUG PRODUCTS; GENES; INSULIN;

BLOOD-BRAIN BARRIER (BBB); BRAIN CAPILLARIES; DRUG TARGETING; ENDOTHELIUM; HUMAN INSULIN RECEPTOR (HIR); RHESUS MONKEY;

ANTIBODIES;

IMMUNOGLOBULIN G; INDIUM 111; INSULIN RECEPTOR ANTIBODY; IODINE 125; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOENGINEERING; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN SCINTISCANNING; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; IMMUNOGLOBULIN VARIABLE REGION; ISOTOPE LABELING; MOUSE; MYELOMA CELL; NONHUMAN; RHESUS MONKEY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BLOOD-BRAIN BARRIER; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MACACA MULATTA; MICE; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; RECEPTOR, INSULIN; RECOMBINANT FUSION PROTEINS;

MACACA MULATTA; MURINAE; PRIMATES;

EID: 33846897981     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21120     Document Type: Article

References (18)

1. Boado RJ, Pardridge WM. 1991. A one-step procedure for isolation of poly A+ mRNA from isolated brain capillaries and endothelial cells in culture. J Neurochem 57:2136-2139.
2. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. 1999. Selective expression of the large neutral amino acid transporter (LAT) at the blood-brain barrier. Proc Natl Acad Sci USA 96:12079-12084.
3. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR, Colman PM, Spinelli S, Alzari PM, Poljak RJ. 1989. Conformations of immunoglobulin hypervariable regions. Nature 342:877-883.
4. Coloma MJ, Lee HJ, Kurihara A, Landaw EM, Boado RJ, Morrison SL, Pardridge WM. 2000. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 17:266-274.
5. Hwang WY, Foote J. 2005. Immunogenicity of engineered antibodies. Methods 36:3-10.
6. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522-525.
7. Kabat EA, Wu TT. 1991. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 147:1709-1719.
8. Koetzner L, Deng S, Sumpter TL, Weisslitz M, Abner RT, Landry DW, Woods JH. 2001. Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys. J Pharmacol Exp Ther 296:789-796.
9. Lee HJ, Boado RJ, Braasch DA, Corey DR, Pardridge WM. 2002. Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. J Nucl Med 43:948-956.
10. Li JY, Sugimura K, Boado RJ, Lee HJ, Zhang C, Dubel S, Pardridge WM. 1999. Genetically engineered brain drug delivery vectors: Cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein. Protein Eng 12:787-796.
11. 18F-fallypride. Neuropsychopharmacol 25:476-488.
12. Nicholls PJ, Johnson VG, Blanford MD, Andrew SM. 1993. An improved method for generating single-chain antibodies from hybridomas. J Immunol Methods 165:81-91.
13. Pardridge WM. 2001. Brain drug-targeting; The future of brain drug development. United Kingdom: Cambridge University Press. 370 p.
14. Pardridge WM, Eisenberg J, Yang J. 1985. Human blood-brain barrier insulin receptor. J Neurochem 44:1771-1778.
15. Pardridge WM, Buciak JL, Friden PM. 1991. Selective transport of an antitransferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther 259:66-70.
16. Pardridge WM, Kang YS, Buciak JL, Yang J. 1995. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 12:807-816.
17. Wu D, Yang J, Pardridge WM. 1997. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest 100:1804-1812.
18. Zhang Y, Schlachetzki F, Pardridge WM. 2003. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 7:11-18.